Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Malaise
Clinical narrative: Severe malaise/feeling sick present with significant interference with activity; Moderate muscle pain with some interference with activity; Significant fever (> 102 °F) ; Significant injection site pain preventing daily activity/significant injection site tenderness (tenderness during rest); Moderate injection site redness; Moderate injection site swelling; Severe fatigue with significant interference with activity; Joint pain with some interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; headache that prevented daily activity OR required any use of a prescription pain reliver; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Severe malaise/feeling sick present with significant interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F) ), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/significant injection site tenderness (tenderness during rest)) and VACCINATION SITE ERYTHEMA (Moderate injection site redness) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Severe malaise/feeling sick present with significant interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F) ), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (headache that prevented daily activity OR required any use of a prescription pain reliver). At the time of the report, MALAISE (Severe malaise/feeling sick present with significant interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F) ), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (headache that prevented daily activity OR required any use of a prescription pain reliver) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: greater than 102 degree Fahrenheit.         Patient had experienced significant injection site pain preventing daily activity, tenderness (tenderness during rest), fever, severe malaise/feeling sick, fatigue with significant interference with activity, moderate injection site redness, swelling, muscle pain, Joint pain with some interference with activity, mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting and headache that prevented daily activity or required any use of a prescription pain relive anytime during the 2 days after COVID-19 vaccination, which occurred on Wednesday, December 20, 2023 and Thursday, December 21, 2023.  Concomitant medications were not reported.   No treatment medication was provided by the reporter.  The Subject ID was reported.  The Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case